Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note released on Sunday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research note on Friday, November 15th.

Aethlon Medical Stock Down 1.4 %

Shares of Aethlon Medical stock opened at $0.65 on Friday. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $2.10. The stock has a market cap of $9.14 million, a P/E ratio of -0.23 and a beta of 1.61. The business’s 50 day moving average is $0.53 and its 200-day moving average is $0.44.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.